Show source-provided references
2. Centers for Disease Control and Prevention (2022, December 23). History of Ebola Virus Disease (EVD) Outbreaks, Available online: https://www.cdc.gov/vhf/ebola/history/chronology.html#anchor_1526565114626.
15. Bezbaruah, R., Chavda, V.P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., and Vora, L. (2022). Nanoparticle-Based Delivery Systems for Vaccines. Vaccines, 10.
10.3390/vaccines10111946 ↗16. Faizi, H.S., Vora, L.K., Nasiri, M.I., Wu, Y., Mishra, D., Anjani, Q.K., Paredes, A.J., Thakur, R.R.S., Minhas, M.U., and Donnelly, R.F. (2022). Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery. Pharmaceutics, 14.
10.3390/pharmaceutics14122817 ↗17. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): A randomised, partly blinded, placebo-controlled, phase 1 trial
10.1016/S0140-6736(17)30575-5 ↗18. Forster, A.H., Witham, K., Depelsenaire, A.C.I., Veitch, M., Wells, J.W., Wheatley, A., Pryor, M., Lickliter, J.D., Francis, B., and Rockman, S. (2020). Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLOS Med., 17.
10.1371/journal.pmed.1003024 ↗24. Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge
10.1038/s41598-018-29135-w ↗27. Depelsenaire, A.C.I., Witham, K., Veitch, M., Wells, J.W., Anderson, C.D., Lickliter, J.D., Rockman, S., Bodle, J., Treasure, P., and Hickling, J. (2021). Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial. PLoS ONE, 16.
10.1371/journal.pone.0255282 ↗30. Andrianov, A.K. (2009). Polyphosphazenes for Biomedical Applications, John Wiley & Sons.
10.1002/9780470478882 ↗31. Andrianov, A.K., and Allcock, H. (2018). Polyphosphazenes in Biomedicine, Engineering & Pioneering Synthesis, American Chemical Society.
10.1021/bk-2018-1298 ↗34. A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime with Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost
10.1097/QAI.0b013e3181354bd7 ↗35. Safety and Immunogenicity of a randomized Phase I prime-boost trial with ALVAC-HIV (vCP205) and Oligomeric gp160 MN/LAI-2 Adjuvanted in Alum or Polyphosphazene
10.1093/infdis/jiw059 ↗36. The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells
10.1016/j.biomaterials.2014.06.043 ↗37. PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies
10.1002/jps.22367 ↗38. Protein stabilization in aqueous solutions of polyphosphazene polyelectrolyte and non-ionic surfactants
10.1021/bm100603p ↗39. Microneedles with Intrinsic Immunoadjuvant Properties: Microfabrication, Protein Stability, and Modulated Release
10.1007/s11095-010-0133-7 ↗41. Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop
10.1038/s41467-018-06113-4 ↗42. Synthesis and biologically relevant properties of polyphosphazene polyacids
10.1021/bm049745d ↗44. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines
10.1016/j.jconrel.2017.06.017 ↗45. Skin Vaccination with Dissolvable Microneedle Patches Incorporating Influenza Neuraminidase and Flagellin Protein Nanoparticles Induces Broad Immune Protection against Multiple Influenza Viruses
10.1021/acsabm.1c00240 ↗46. Dissolving polymer microneedle patches for influenza vaccination
10.1038/nm.2182 ↗47. Dissolvable Microneedle Patches for the Delivery of Cell-Culture-Derived Influenza Vaccine Antigens
10.1002/jps.23019 ↗48. Lee, B.-M., Lee, C., Lahiji, S.F., Jung, U.-W., Chung, G., and Jung, H. (2020). Dissolving microneedles for rapid and painless local anesthesia. Pharmaceutics, 12.
10.3390/pharmaceutics12040366 ↗49. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate
10.1073/pnas.2112008119 ↗50. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells
10.1128/JVI.01403-18 ↗51. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein
10.1128/JVI.02172-15 ↗52. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site
10.1016/j.celrep.2016.04.026 ↗54. Molecular-Level Interactions of Polyphosphazene Immunoadjuvants and Their Potential Role in Antigen Presentation and Cell Stimulation
10.1021/acs.biomac.6b01251 ↗55. Cationic Fluoropolyphosphazenes: Synthesis and Assembly with Heparin as a Pathway to Hemocompatible Nanocoatings
10.1021/acsabm.1c01099 ↗60. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
10.1016/j.vaccine.2016.02.033 ↗61. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses
10.3389/fimmu.2021.703986 ↗